AIAISci
中文
clinical updateBiotech

Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer

Clinical/translation signal: Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer

Occurred SourceClinicalTrials.govapprovedSourceClinicalTrials.gov

Factual summary

What happened

ClinicalTrials.gov registry update for Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer

SourceClinicalTrials.gov

Why it matters

Clinical trial registry updates are translation signals, not commercialization claims by themselves.

SourceClinicalTrials.gov

Limitations

ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.

SourceClinicalTrials.gov

Linked output

Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancerclinical trial

People

No reviewed person relationship is attached to this event.

Organizations

M.D. Anderson Cancer Center

Topics

No reviewed topic relationship is attached to this event.

Problems

No reviewed problem relationship is attached to this event.

Relationship evidence

Timeline

  1. clinical updateTrastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
    SourceClinicalTrials.gov